- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30437
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
Abstract
Potential New Treatment Target for Viral Hepatitis
Pei-Jer Chen
Hepatitis Reseach Center, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei, Taiwan R.O.C.
Currentl treamtments for chronic hepatitis B have improved the clinical outcomes of CHB patients. anti-viral Nucs satisfactorily suppress viral replication and prevent the subsequent new rounds of HBV infection in the liver. Interferon augments the host immune responses and occaionally achieves durable viral control or even eradication. However, the likelyhood of current therapies is still deemed low in removing HBV cccDNA or in clearing HBsAg. New therapies targets to viral or host molecules other than viral polymerase are actively explored. Peptides or antibodies effectively preventing HBV infection have been developed and even in early phase clinical trials. Small molecules in disrupting HBV capsid formation also showed some promising progress. New cytokines or small molecules controlling or degrading cccDNA are actively explored. Finally, the potent immuno-enhancers, such as TLR 4/7/9 agonists, have domenstrated signficant anti-HBV acitivities in the relevant animal models. These new progresses will pave the way for the next generation anti-HBV therapies aiming to curative therapies.
Assigned speakers:
Dr. Pei-Jer Chen, National Taiwan University College of Medicine , Taipei , Taiwan R.O.C.
Assigned in sessions:
09.06.2013, 10:30-12:00, Clinical Tracks (CT), CT 3-2, Novel Treatments and Emerging Strategies for Chronic Hepatitis B, Hall 2
|
|